.25 glp 1 Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead The first ever FDA-approved GLP-1

Tirzepatide may have broader anti-inflammatory mechanisms

Expert-led care: Providers adjust your dose, manage side effects, and tailor treatment to your health history

Revising it for intellectual content: C

IQVIA estimates that at least one in three people living with obesity worldwide resides in a country where semaglutide is available off-patent in 2026

We adjust the ramp to balance comfort with progress

Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens